Xeris Biopharma Holdings, Inc.

XERS
About the company

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

Country: United StatesPrice: $16.66Market Cap: $3.0B

Investment snapshot

12%positive consensus
Scored 1d ago

Positive

2

BUY / PASS

Neutral / negative

1 / 13

NEUTRAL / FAIL

Median fair value

$0.11

-99.3% vs price

Models with upside

0 / 17

Positive margin of safety

Strongest signal

5 of 8 pass — Buffett, Akre and Sleep object

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #978 (Top 31.6%)BUYFAILFAILFAILFAILFAILPASSFAILFAILFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/A-15045.5%N/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

TTM ended 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-02

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-02

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · Balance sheet at 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Qualitative assessment

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-02

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-02

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-05

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-05

Score computed: 2026-11-14

Where It Passes

  • Efficiency63% pass✓ 6✗ 5▾

    5 of 8 pass — Buffett, Akre and Sleep object

    Current Ratio2.15
    ✓Graham>= 2.0
    ROIC (3-5 yr avg)-34.2%
    ✗Buffett> 10%
    ROIC - WACC-44.2%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)165.1%
    ✓Greenblatt> 25%
    Current Ratio Change YoY1.67 -> 2.19
    ✓PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY0.63x -> 0.76x
    ✓PiotroskiImproved YoY
    Current Assets / Current Liabilities2.15
    ✓Dreman> 1.5
    Return on Invested Capital15.5%
    ✓Munger> 15%
    ROIC (high and growing)FY2023: ROIC=-18.9%; FY2024: ROIC=-13.1%; FY2025: ROIC=8.4%
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROIC8.4% (RR=100% x ROIC=8.4%)
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/5 years above 12% (latest 8.4%)
    ✗SleepROIC > 12% in a majority of years

Where It Falls Short

  • Valuation0% pass✓ 1✗ 27▾

    No clean pass — all 13 investors flag at least one valuation criterion

    Price / 3-yr avg EPS
    ✗Graham<= 15x
    Price-to-Book Ratio202.3x
    ✗Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value1.5%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=1.5%, ROC=165.1%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)96.7x
    ✗Dreman< 8x
    Price / Book Value per Share202.3x
    ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Valuation ReasonablenessOE Yield=0.1%
    ✗MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF Yield
    ✗PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/B=202.3x
    ✗MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Price / FCF per Share
    ✗Ackman<= 25
    Price vs. Trailing Low468% of trailing low ($3.56)
    ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization-0.21%; #3252/6340 (top 51.3%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+0.0160; #5153/6449 (top 79.9%)
    ✗AsnessTop 30% of eligible cross-section
    Price / Diluted EPS
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per ShareN/A (non-positive TBVPS)
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change
    ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+0.1210; #4225/5247 (top 80.5%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date+184.79%; #161/6202 (top 2.6%)
    ✓OshaughnessyTop 10% of eligible cross-section
  • Profitability6% pass✓ 7✗ 28▾

    15 of 16 flag XERS's profitability — Graham, Buffett, Lynch +12 more

    Positive EPS (10 years)0/7 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)1/7 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-151.1%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)8.5% (latest)
    ✓BuffettStable or rising over 10 years
    Free Cash Flow Proxy$-122.5M
    ✗BuffettPositive and growing
    Earnings Variance (10-yr CoV)N/A (negative mean EPS)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE-13.3%
    ✗Lynch> 15%
    EBIT / Enterprise Value1.5%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=1.5%, ROC=165.1%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets0.14%
    ✓PiotroskiROA > 0
    ROA Change YoY-16.97% -> 0.14% (delta: +17.12%)
    ✓PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=7.46%, ROA=0.14%
    ✓PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY81.9% -> 85.4%
    ✓PiotroskiImproved YoY
    Pre-Tax Income / Revenue0.2%
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity-13.3%
    ✗Dreman> 12%
    Margin of SafetyP/B=202.3x
    ✗PabraiP/B < 1.5 or P/E < 15
    Return on Equity-111.4% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency1/6 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue12.7%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity-13.3%
    ✗Ackman>= 15%
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-26.8% (2023) -> 8.5% (2025)
    ✓TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 82.5% -> 85.4%, operating margin -26.8% -> 8.5%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization-0.21%; #3252/6340 (top 51.3%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets+65.00%; #404/3702 (top 10.9%)
    ✓AsnessTop 30% of eligible cross-section
    Net income / positive book equity-13.32%; #3523/5226 (top 67.4%)
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.1328; #3819/5884 (top 64.9%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years0/6 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Debt & Leverage8% pass✓ 3✗ 12▾

    11 of 12 flag XERS's debt & leverage — Graham, Buffett, Lynch +8 more

    LT Debt vs Net Current AssetsLT Debt $189.7M vs NCA $154.8M
    ✗GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: 3.89, IC: 1.7x
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity3.89
    ✗Lynch< 0.33
    Cash - Long-term Debt$-58.6M
    ✗LynchPositive preferred
    LT Debt / Total Assets Change67.17% -> 57.45%
    ✓PiotroskiDecreased YoY
    Current Assets / Current Liabilities2.15
    ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity3.89
    ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
    Debt Levels3.89
    ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=1.7x, D/EBITDA=3.9x
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity3.89
    ✗Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-3.8888; #4023/4210 (top 95.6%)
    ✗AsnessTop 30% of eligible cross-section
  • Cash Flow10% pass✓ 2✗ 10▾

    9 of 10 flag XERS's cash flow — Buffett, Lynch, Dreman +6 more

    Free Cash Flow Proxy$-122.5M
    ✗BuffettPositive and growing
    FCF Positive and Growing$-96.6M
    ✗LynchPositive and growing
    Operating Cash Flow$28.6M
    ✓PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=7.46%, ROA=0.14%
    ✓PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)96.7x
    ✗Dreman< 8x
    P/E or FCF Yield
    ✗PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive0/2 years FCF positive
    ✗MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap
    ✗Ackman>= 4%
    Price / FCF per Share
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency1/6 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures
    ✗Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization
    ✗OshaughnessyTop 10% of eligible cross-section
  • Growth13% pass✓ 4✗ 9▾

    7 of 8 flag XERS's growth — Graham, Lynch, Dreman +4 more

    EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthInv: 14.0% vs Rev: 38.4%
    ✓LynchInventory growth < Revenue growth
    EPS Growth Direction$-2.14 (2020) -> $0.00 (2025)
    ✗DremanPositive over recent years
    EPS CAGR
    ✗Dreman> 5% annualized
    Positive Net Income Frequency1/6 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth43.7%
    ✓Ackman>= 5%
    Positive EPS Growth Frequency5/5 years with positive EPS growth
    ✓AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 82.5% -> 85.4%, operating margin -26.8% -> 8.5%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR70.2%
    ✓SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
  • Verdicts13% pass✓ 2✗ 14▾

    Split decision: 13 FAIL · 1 BUY · 1 PASS · 1 NEUTRAL

    Overall verdict
    ✗GrahamFAIL (2/9)✗BuffettFAIL (1/9)✗LynchFAIL (1/7)✗GreenblattRank #978✓PiotroskiBUY (F-Score 8)✗DremanFAIL (2/11)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (0/6)✗MarksFAIL (0/5)✓AckmanPASS (4/9)✗TempletonFAIL (2/8)✗SleepFAIL (1/6)✗AsnessFAIL (Rank #1681/2370 (Top 70.9%))✗NeffFAIL (1/6)✗SchlossFAIL (1/7)•OshaughnessyNEUTRAL (Not ranked)

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Pharmaceutical Products
SIC Sector: Chemicals & Pharmaceuticals
Size: Mid Cap($3.0B)
Revenue: $291.8M+43.7% YoY
Net Income: $554000.00+101.0% YoY

Financial Snapshot

Operating Margin8.5%
Return on Equity4.0%
Debt / Equity16.10
Current Ratio2.19
EPS (Diluted)$0.00
Shares Retired−11.2% / −18.3% 2y

Similar Companies

MRKMerck & Co., Inc.
$364.3B
ABTABBOTT LABORATORIES
$188.0B
BMYBRISTOL MYERS SQUIBB CO
$129.7B
TECHBIO-TECHNE Corp
$11.4B

Shareholder Return

Fiscal 2025

Issued 11.2% of shares last year, 18.3% issued over two.

Buybacks
—
Dividends
—

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2026-09-30

2025-10-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: revenue, net income, operating income, ebit, interest expense, operating cash flow, depreciation amortization.

Q3 FY 2026

2026-07-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow.

Q2 FY 2026

2026-04-01 – 2026-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization.

Q1 FY 2026

2026-01-01 – 2026-03-31

Sources
FY 2025
Sources
  • 10-K · 2026-03-02
FY 2024
Sources
  • 10-K · 2025-03-06
FY 2023
Sources
  • 10-K · 2024-03-06
FY 2022
Sources
  • 10-K · 2023-03-08
FY 2021
Sources
  • 10-K · 2022-03-11
Market Cap$3.0Bcurrent------$1.2Best.$532.0Mest.$345.5Mest.$170.2Mest.$263.5Mest.
Revenue$368.3M↑38%$107.2M↑44%$92.1M↑29%$83.1M↑38%$291.8M↑44%$203.1M↑24%$163.9M↑49%$110.2M↑122%$49.6M
Operating Income$46.8M↑377%$16.9M↑151%$5.2M↑15%$7.9M↑356%$24.9M↑174%-$33.6M↑24%-$44.0M↑46%-$81.9M↑29%-$115.2M
Net Income-$6.5M↑58%$11.3M↑1718%-$31.1M↓1513%$2.2M↑124%$554.0K↑101%-$54.8M↑12%-$62.3M↑34%-$94.7M↑23%-$122.7M
EPS (Diluted)--$0.06$-0.18↓1700%$0.01↑117%$0.00↑100%$-0.37↑18%$-0.45↑36%$-0.70↑55%$-1.55
Gross Margin————85.4%↑4%81.9%↓1%82.5%↑4%79.5%↑9%73.1%
Operating Margin12.7%↑245%15.8%↑74%5.6%↓10%9.5%↑285%8.5%↑151%-16.6%↑38%-26.8%↑64%-74.3%↑68%-232.2%
ROE-13.3%↓101%———4.0%↓98%185.2%↓80%917.9%↑538%-209.5%↓63%-128.9%
Total Debt$189.7M↓14%$189.7M↓14%$252.6M↑16%$221.2M↓4%$220.3M↓5%$232.1M↑22%$190.9M↑2%$187.1M↑112%$88.1M
Shareholders' Equity$48.8M↑5766%$48.8M↑5766%-$9.7M↑50%$13.0M↑137%$13.7M↑146%-$29.6M↓337%-$6.8M↓115%$45.2M↓53%$95.2M
Current Ratio2.15↑12%2.15↑12%1.45↓26%2.12↑23%2.19↑31%1.67↑2%1.64↓35%2.54↑41%1.80
Debt / Equity3.89↑102%3.89↑102%-25.95↓129%17.00↑360%16.10↑305%-7.84↑72%-28.15↓780%4.14↑348%0.92
Operating Cash Flow$73.6M↑598%$35.5M↑92%$8.3M↑4440%$9.9M↑198%$28.6M↑177%-$37.0M↑21%-$47.0M↑54%-$102.9M↓8%-$95.5M
Free Cash Flow-----------------$96.6M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Pharmaceutical Products

XERS vs Peers — Financial Grading

Revenue$291.8MBottom 25%
Net Income$554000.00Median
ROE4.0%Median
D/E16.10Bottom 25%
Op. Margin8.5%Median
Curr. Ratio2.19Median
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11